Oncothermia brings new hope to cancer patients

Saudi Gazette

RIYADH — Driven by a great desire to help cancer patients and reduce their suffering, Prof. Andras Szasz, founder and head of research at Oncotherm company, has developed a painless therapy to complement cancer treatment.

Known as oncothermia, it is a modulated-electro-hyperthermia for oncological use. It is a fast developing supportive, complementary treatment method against different types of tumors. The Saudi Food and Drugs Authority recently approved the procedure.

The principles of treatment are based on the classical method of hyperthermia, but the aim, beside the absolute increase in temperature, is especially the direct electric-field energy absorption in the extracellular liquid and destroying the membrane of the cancer cells.

Oncothermia’s effect is synergic to radiotherapy and to numerous chemotherapies. Furthermore, it leads to an increased immunogenicity and effectively reduces the pain of the patient.

Saudi Gazette met with Prof. Szasz, who was on a visit to Riyadh and Jeddah recently and had multiple meetings with stakeholders about his invention and how it helps cancer patients across five continents.

“I started working on my invention since 1988. The journey was very long and it was not easy. There were many trials and errors and countless procedures to make it recognizable,” he said.

“In 2002, we started spreading my invention through my company, which is only responsible for serious medical tasks. Currently, we have spread it in 35 countries and now 200,000 oncothermia procedures are performed annually,” he added.

The invention had produced encouraging results in enhancing the survival time of cancer patients. “The cases treated by oncothermia had shown a 20 percent improvement in the quality of lives for patients. However, we cannot separate the invention from other crucial factors, such as medications and a determination for survival,” he emphasized.

The researcher said oncothermia is absolutely safe and has no side effects. “It can be used for all age groups, female and male, and all types of cancer except leukemia.

I have strong hope that Saudi hospitals will apply this method in treatment,” Szasz said.

Dr. Hamad Al-Omar, chairman of the National Blood and Cancer Center, said there were more than 20,000 new cancer cases in the Kingdom in 2017, in addition to existing patients. “The Ministry of Health is working hard to enhance services given to cancer patients. We held several talks with Prof. Szasz and we hope to adopt this new method in our public and private hospitals,” he said.

Dr. Al-Omar said the main causes of cancer in the Kingdom are smoking, lack of exercise and unhealthy diet. “However, with the new treatment methods, we can think of cancer as a chronic disease, not a fatal disease,” he stressed.

He said cancer can be fully cured while diabetes for example is incurable. “Unfortunately, people think of cancer as a fatal disease that is incurable when the truth is most cancer cases can be cured,” Al-Omar said.

He emphasized that prevention is much better than cure. “By adopting a healthy lifestyle, we can reduce the possibility of us getting diseases. If we look back 10 years, diabetes affected only 5 percent of people while today it is 30 percent, all because of the unhealthy lifestyles,” he concluded.



Board inauguration

Oncotherm Kft. is proud of its ability to contribute to strengthening the practical aspect of education. This task is performed by the Outsourcing Department of Biotechnics of Szent István University at Oncotherm Kft. in Budaörs.

Oncotherm Kft. and the Outsourcing Department of Biotechnics are cooperating in the overall harmony of the university education and the industry, especially by training the students of the doctoral school. On September 14, 2017, an information board was hanged up, the inauguration of which was brought about by the change of the site of Oncotherm Kft.

Oncotherm Kft. thanks to all members of the board promotion for their participation. The fact was particularly honored that we were able to welcome prominent professors at the inauguration, namely:

Dr. Gyula Péter Szigeti – Vice President for Research and Development of the National Research, Development and Innovation Office
Prof. Dr.János Tőzsér – Rector of Szent István University
Prof. Dr. István Szabó – Vice-Rector for International Relations of Szent István University
Prof. Dr. László Kátai –  Dean of the Faculty of Mechanical Engineering at Szent István University
Dr. Tibor Krenács – 1st Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, senior research fellow

The event was honored by the presence of two former PhD students who had already participated in the training program which began in 1994:
Prof. Dr. Gabriella Hegyi – Head of Department of the Faculty of Health Sciences Complementary Department of Medicine at Pécsi Tudományegyetem and Director of Konfucius Institute
Prof. Dr. Ibolya Zsoldos – Head of Department of Materials Science and Technology at István Széchenyi University, Deputy Assistant Dean of the Audi Hungaria Vehicle Engineering Faculty

Board inauguration was followed by the presentation of the company’s results and publications and the presentation of the departments of the company.

Internal charge redistribution and currents in cancerous lesions

Andars Szasz, Gyula Vincze, Gyula Szigeti, Oliver Szasz


The tissues in biological objects from the point of view of electromagnetic effects have to be modeled by not only their conductivity. The electric field induced double ionic layer, constructed by electrolytic diffusion, has to be counted. We describe this phenomenon by micro (frequency dispersion phenomena), and by macro (interfacial polarization), as well as more generalized by Nernst-Planck cells. The results are applied to cancerous tissues in the healthy neighborhood. Our objective is to show the space charge distribution and redistribution that generate injury currents and other internal currents in the development of cancer. We show some aspects of the theoretical basis of modulated electro-hyperthermia (mEHT, trade name oncothermia, also used name: nanothermia), which uses an anti-injury current in the micro-range to limit the proliferation process, similar to the macro-range electrochemotherapy (ECT) processes.

For detailed information please follow the link: